Skip to main content
logo
Apimeds Pharmaceuticals US, Inc. (APUS)
NYSEAMERICAN: APUS · Real-Time Price · USD
2.300
-0.120 (-4.96%)
Sep 8, 2026, 4:00 PM EDT - Market closed

APUS Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-5.16-1.39-0.78-0.67-1.03
Stock-Based Compensation
1.93-0.070.190.19
Other Operating Activities
0.080.120.040.030.01
Change in Accounts Payable
0.150.540.05-00
Change in Other Net Operating Assets
-2.220-0.010-0
Operating Cash Flow
-5.21-0.73-0.63-0.45-0.82
Operating Cash Flow Growth
-----

Financing Activities

Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-0.330.010.28-
Long-Term Debt Issued
----0.4
Total Debt Issued
0.340.330.010.280.4
Short-Term Debt Repaid
---0.03--
Total Debt Repaid
-0.09--0.03--
Net Debt Issued (Repaid)
0.250.33-0.020.280.4
Issuance of Common Stock
11.95-1.06--
Financing Cash Flow
12.20.331.030.280.4

Net Cash Flow

Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
6.96-0.410.4-0.17-0.42

Free Cash Flow

Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21
Levered Free Cash Flow
-3.39-0.29-0.35-0.2-
Unlevered Free Cash Flow
-3.33-0.22-0.32-0.18-

Additional Metrics

Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
-2.070.540.04-00
SEC Filings: 10-K · 10-Q